单酰甘油脂肪酶抑制可保护硬化性胆管炎小鼠模型中的肝损伤
本研究在DDC喂养的野生型和MGL-/-小鼠及Mdr2-/-小鼠模型中,探究单酰甘油脂肪酶(MGL)在硬化性胆管炎中的作用。MGL敲除或药理抑制(JZL184)可减轻胆汁淤积性肝损伤、炎症和胆道纤维化,改善肝酶,并调节脂肪酸/胆汁酸代谢。MGL抑制可能成为硬化性胆管炎的潜在治疗策略。
要点
- MGL敲除减轻DDC诱导的胆道纤维化和炎症,降低血清肝酶。
- JZL184抑制MGL可改善DDC喂养WT小鼠和Mdr2-/-小鼠的胆汁淤积性肝损伤。
- MGL沉默减少肠道PGE2积累并上调PPARα/γ活性,从而减轻炎症。
核心结论
- MGL抑制可减轻小鼠硬化性胆管炎模型的胆汁淤积性肝损伤和胆道纤维化,提示其作为潜在治疗靶点。
研究设计与样本
- 研究在DDC喂养的野生型和MGL-/-小鼠中诱导硬化性胆管炎,并在Mdr2-/-小鼠中测试JZL184药理抑制。
- 采用血清生化、肝组织学、基因表达和western blot评估胆汁酸和脂肪酸合成/转运,并分析肠道脂肪酸和粪便微生物组。
- 在Caco2细胞中进行转染和沉默实验。
主要发现
- MGL-/-小鼠免受DDC诱导的胆道纤维化和炎症,血清肝酶降低,脂肪酸/胆汁酸代谢和β-氧化增加。
- JZL184抑制MGL改善DDC喂养WT小鼠的胆汁淤积性损伤,并保护Mdr2-/-小鼠免受自发性肝损伤,改善肝酶、炎症和胆道纤维化。
- MGL沉默减少肠道前列腺素E2积累并上调过氧化物酶体增殖物激活受体α和γ活性,从而减少炎症。
临床怎么用
- MGL抑制可能作为硬化性胆管炎的潜在药物治疗方向,但尚未在人体研究中验证。
局限性
- 研究仅基于小鼠模型和体外细胞实验,尚未在人类中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Monoacylglycerol lipase (MGL) is the last enzymatic step in triglyceride degradation, hydrolyzing monoglycerides into glycerol and fatty acids (FAs) and converting 2-arachidonoylglycerol into arachidonic acid, thus providing ligands for nuclear receptors as key regulators of hepatic bile acid (BA)/lipid metabolism and inflammation. We aimed to explore the role of MGL in the development of cholestatic liver and bile duct injury in mouse models of sclerosing cholangitis, a disease so far lacking effective pharmacological therapy. APPROACH AND RESULTS: To this aim we analyzed the effects of 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) feeding to induce sclerosing cholangitis in wild-type (WT) and knockout (MGL-/- ) mice and tested pharmacological inhibition with JZL184 in the multidrug resistance protein 2 knockout (Mdr2-/- ) mouse model of sclerosing cholangitis. Cholestatic liver injury and fibrosis were assessed by serum biochemistry, liver histology, gene expression, and western blot characterization of BA and FA synthesis/transport. Moreover, intestinal FAs and fecal microbiome were analyzed. Transfection and silencing were performed in Caco2 cells. MGL-/- mice were protected from DDC-induced biliary fibrosis and inflammation with reduced serum liver enzymes and increased FA/BA metabolism and β-oxidation. Notably, pharmacological (JZL184) inhibition of MGL ameliorated cholestatic injury in DDC-fed WT mice and protected Mdr2-/- mice from spontaneous liver injury, with improved liver enzymes, inflammation, and biliary fibrosis. In vitro experiments confirmed that silencing of MGL decreases prostaglandin E2 accumulation in the intestine and up-regulates peroxisome proliferator-activated receptors alpha and gamma activity, thus reducing inflammation. CONCLUSIONS: Collectively, our study unravels MGL as a metabolic target, demonstrating that MGL inhibition may be considered as potential therapy for sclerosing cholangitis.
引用
- Tardelli M, Bruschi FV, Fuchs CD, et al. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis. Hepatology. 2019. PMID: 31505038. doi:10.1002/hep.30929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。